BPC-157 vs TB-500
Last updated: 2026-05-25
- BPC-157 is derived from gastric juice; TB-500 is a synthetic form of Thymosin Beta-4 from the thymus gland.
- BPC-157 research focuses on gut protection and tendon repair; TB-500 research emphasizes wound healing and cardiac regeneration.
- BPC-157 primarily modulates nitric oxide and growth factor receptors; TB-500 works through actin sequestration and cell migration.
- Both are classified as research peptides with medium evidence levels and primarily preclinical data.
- TB-500 has more research in cardiovascular models; BPC-157 has more research in gastrointestinal models.
BPC-157 and TB-500 are both tissue-repair peptides studied in preclinical models, but they differ in origin, mechanism, and primary research focus areas.
Side-by-Side Comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| What It Is | A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties. | A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery. |
| Typical Research Focus | ||
| Proposed Mechanisms |
|
|
| Evidence Snapshot |
Medium Evidenceresearch peptide
|
Medium Evidenceresearch peptide
|
| Cautions |
|
|
BPC-157
- What It Is
- A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties.
- Research Focus
- Evidence
- Medium Evidence
- Cautions
-
- Most studies are preclinical (animal models)
- Only three small human studies published, all from one research group without placebo controls
- Long-term safety profile not established in humans
TB-500
- What It Is
- A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery.
- Research Focus
- Evidence
- Medium Evidence
- Cautions
-
- Primarily studied in animal models, though 2026 human cardiac trial data has emerged
- Human clinical data is still limited
- Not FDA-approved
When Researchers Compare Them
Researchers frequently compare BPC-157 and TB-500 because both peptides have demonstrated tissue-protective and repair-promoting properties in preclinical studies. However, their mechanisms of action differ substantially.
BPC-157 originates from a sequence found in human gastric juice and has been primarily studied for its cytoprotective effects on the gastrointestinal tract, as well as tendon and ligament healing. Its proposed mechanisms involve nitric oxide modulation, angiogenesis promotion, and growth factor receptor upregulation.
TB-500, a synthetic analog of Thymosin Beta-4, is one of the most abundant intracellular proteins. Research has focused on its role in cell migration via actin sequestration, wound closure, and cardiac tissue repair following ischemic events. Some researchers have explored whether the two peptides may have complementary mechanisms, though combined-use studies remain limited.
Peptide Profiles
Citations
- [1] Sikiric P. et al. — Pentadecapeptide BPC 157 and its effects in various models. Curr Pharm Des. 2018 Source
- [2] Goldstein AL. et al. — Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012 Source
- [3] BPC-157 Research Results 2026: Preclinical Studies on Tissue Repair — Spartan Peptides Source
- [4] FDA PCAC Notice of Meeting: BPC-157 Bulk Drug Substances — Federal Register. April 16, 2026 Source
- [5] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing — PMC 2026 Source
- [6] FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee Source
- [7] TB-500 and Cardiac Recovery: What the 2026 Human Trial Data Shows — PeptIQ 2026 Source
Explore Research Tools
Use calculators for reconstitution, dosing references, and more.
Use PepTracker Pro ToolsRelated Peptides
GHK-Cu
High EvidenceA naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.
KPV
Medium EvidenceA tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties.